Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. (Q53059036)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

0 references

0 references

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Marie Therese Armentero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Giovanna Levandis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Giulia Ambrosi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Elena Montepeloso

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Gian Filippo Antoninetti

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

1 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuropathology & Experimental Neurology

13 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

414-424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

Levodopa motor complications in Parkinson's disease

13 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Treatment strategies for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Therapies in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Association of coffee and caffeine intake with the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Targeting adenosine A2A receptors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Identification of nuclear factor 1 (NF1) as a transcriptional modulator of rat A(2A) adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine receptor signaling in the brain immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Cannabinoids and neuroprotection in basal ganglia disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Cannabinoids and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Unbiased stereological estimation of the number of neurons in the human hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Endocannabinoids mediate neuron-astrocyte communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Astrocytes and Therapeutics for Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

The 6-hydroxydopamine model: news from the past

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine A(2A) receptor mediates microglial process retraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Microglial cell activation and proliferation precedes the onset of CNS autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Adenosine A(2A)-cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

Comparison of polarization properties of human adult microglia and blood-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064